Background. Mycophenolate-related anemia and leukopenia are well-known toxicities after transplantation. Toxicity leads to dose reduction, addition of colony-stimulating factors or erythropoietin, or discontinuation of immunosuppressive therapy. The causes of and risk factors associated with toxicity are unclear. Methods. We studied the association between mycophenolate-related anemia and leukopenia and 2724 single nucleotide polymorphisms (SNP) in 978 patients undergoing living or deceased donor kidney transplant. Patients were followed up to time of first anemia (hemoglobinϽ10 gm/dL or hematocritϽ30%) or first leukopenia (white blood cell [WBC] count Ͻ3000 cells/mm
Few data are available regarding risk factors for mycophenolate-related toxicity. Studies suggest that high mycophenolic acid (MPA) area under the curve or trough concentrations are associated with greater risk of anemia or leukopenia; however, others find no association. (3-5, 7, 10, 17-21) We hypothesized that genetic variation may be associated with the development of mycophenolaterelated anemia and leukopenia. Our long-term goal is to identify individuals at risk for toxicity before transplantation and provide alternative immunosuppression strategies for these individuals.
RESULTS

Patients and Mycophenolate-Related Toxicity
Demographics of the 978 subjects are shown in Table 1 . Mycophenolate mofetil was the initial mycophenolate in 971 subjects and mycophenolate sodium in seven subjects. Seven subjects were switched from mycophenolate mofetil to mycophenolate sodium during the study. Nearly all patients received a calcineurin inhibitor with mycophenolate and over half received thymoglobulin induction (Table 2) .
Complete clinical data were available to evaluate time to mycophenolate-related anemia in 918 patients. Anemia occurred in 87 (1.5%) individuals within the first 6 months posttransplant (Table 2) . Patients experiencing the event received mycophenolate a median (95% CI) of 45.0 days (34 -55 days) before the development of anemia. The median (range) hemoglobin at time of anemia was 9.3 g/dL (7.1-10.0 g/dL), and hematocrit 28% (11.2%-29.9%). Interventions for those with anemia were mycophenolate dose reduction (nϭ27), discontinuation (nϭ1), and erythropoietin with mycophenolate continuation (nϭ68). Nine patients underwent more than one of the above changes.
Time to mycophenolate-related leukopenia was evaluable in 978 patients. Leukopenia occurred in 224 (22.9%) To assess whether these SNPs were independent predictors, a multiple-SNP Cox regression model for time to anemia was developed from three of the four top SNPs from the single SNP analysis and the above associated clinical factors (Table 4) . Of the two SNPs from HUS1, only one SNP (rs1056663) was included due to high linkage disequilibrium (r 2 ϭ1.0). All three of the SNPs remained associated with time to anemia at the 0.005 level adjusting for the other SNPs and the clinical factors. For every increase in 10 years of age from the mean age, the hazard of anemia was increased by 1.28 (95% CI 1.09 -1.50) and need for posttransplant dialysis increased hazard of anemia by 2.44 (95% CI 1. 42-4.20) . Antiviral drug use was not significant in the final model at the 5% level.
Clinical Factors and SNPs Associated With Mycophenolate-Related Leukopenia
Clinical factors associated with leukopenia were corticosteroid use (Pϭ0.018), weight at time of transplant (linear, Pϭ0.018), previous kidney transplant (Pϭ0.038), deceased donor (Pϭ0.051), and negative-recipient and positive-donor CMV serostatus (Pϭ0.006). The effect of each SNP was then tested individually in Cox regression models adjusting and not adjusting for the above clinical factors, and stratifying by center. Eighteen SNPs had a P less than 0.01 and 95% CIs that did not cross one; however, they were not significant at an FDR of 20% (Table 5) .
DISCUSSION
This is the first pharmacogenetic study to evaluate the association between SNPs and mycophenolate-related toxicities using a broad panel of SNPs in a large population (nϭ978). Limited numbers of candidate SNPs in genes related to mycophenolate metabolism, transport or its target have been evaluated toward toxicity in small analyses (22) (23) (24) . Previously no association between SNPs of the inosine monophosphate dehydrogenase-1 (IMPDH) gene and leukopenia were found in 191 kidney transplant recipients; although some of these SNPs increased the risk of acute rejection (22) . A recent analysis of IMPDH2 and ABCC2 SNPs in 59 pediatric heart recipients found an association between the IMPDH2 SNP (rs11706052) and neutropenia, which required dose holding but no association with anemia or thrombocytopenia (23) . In our analysis, these and other IMPDH and ABCC2 SNPs were not found to be associated with toxicity.
We identified multiple novel SNPs potentially associated with anemia (Table 3) . Potential SNPs for anemia were in the interleukin-12A (IL-12A), checkpoint homolog protein (HUS1) and cytochrome P4502C8 (CYP2C8) genes which were each significant in single-SNP analysis after accounting for a 20% FDR, and remained independent predictors in the multiple-SNP analysis. The IL-12 gene is important in the regulation of T-cell response and is involved in innate and adaptive immunity, inflammation, and autoimmune disease (25, 26) . IL-12 mRNA expression and IL-12 levels have been shown to be elevated in patients with aplastic anemia (27) . The HUS1 protein has multiple functions and is involved in cellular response to DNA damage (28) . It is thought to participate in cell cycle arrest, activation of DNA repair pathways, movement of DNA repair proteins to sites of damage, activation of transcription, and apoptosis (29) . It is possible that altered HUS1 function may place a cell at higher risk of cytotoxicity. CYP2C8 is involved in drug metabolism and the 6-O-desmethyl-mycophenolate acid metabolite is produced by CYP3A4/5 and probably CYP2C8 (30 -32) . Therefore, SNPs of this enzyme may affect MPA metabolism resulting in higher exposure.
We identified SNPs potentially associated with leukopenia (Table 5 ). These SNPs were not significant after accounting for a 20% FDR in the single SNP analysis. We consider these SNPs exploratory and will require validation. The most promising SNPs in the leukopenia analysis were from the vascular cell adhesion molecule (VCAM) and solute carrier organic anion transporter (SLCO1B1, rs4149056) genes. VCAM is expressed on vascular endothelial cells after stimulation by cytokines that mediate leukocyte-endothelial cell adhesion and signal transduction and regulates the migration of stem cells and homing of lymphocytes (33) . Mice with deficient VCAM-1 develop leukocytosis (34) . SLCO1B1 is an influx hepatic transporter expressed at the basolateral membrane of hepatocytes and to a lesser degree in spleen, mammary gland, and testis. The SLCO1B1 and SLCO1B3 transporters are substrates for the MPA glucuronide metabolite (35) . The SLCO1B1*5 (rs4149056, c.521TϾC) SNP, which we identified as possibly important toward leukopenia is also associated with serum bilirubin, statin pharmacokinetics, statin adverse events, irinotecan pharmacokinetics, and hematologic toxicity (36 -42) . No association between MPA pharmacokinetics and SLCO1B1 SNPs has been observed by others, although trends show that individuals with rs4149056 have higher MPA concentrations (35, 43) . We also evaluated SLCO1B3 SNPs in our study and we found no association with toxicity; however, it is possible that other SLCO1B3 SNPs not on our SNP chip are important. Although conflicting, SLCO1B3 SNPs have been associated with MPA pharmacokinetics but only in patients receiving concomitant tacrolimus or sirolimus (35, 43) . The mechanism by which SLCO1B1 SNPs might increase the risk of leukopenia may be through accumulation of MPA and/or its active metabolites in the blood due to altered hepatic trans- port or accumulation within white blood cells. There were no overlapping SNPs between leukopenia and anemia, suggesting different mechanisms by which these toxicities occur.
The pathogenesis of anemia and leukopenia after transplantation is multifactorial and these factors were evaluated in our study (44 -48) . Interestingly, we did not find the use of corticosteroids protective toward leukopenia in the final models. Such therapies have been associated with higher white counts (21) but have not been universally observed (10, 49) . Although controversial, most data suggest that high total MPA concentrations are associated with toxicity (3-5, 7, 10, 17, 18, 20, 21, 50) . Most centers participating in our study do not monitor MPA concentrations and data are not available; therefore, we cannot exclude the possibility of an association between concentration and toxicity. Renal impairment has also been associated with leukopenia (21), which may be due to accumulation of the active MPA acylglucuronide metabolite or high unbound MPA concentrations that may occur during renal impairment (20) . However, in our analysis SCr early posttransplant was not associated with toxicity.
The mechanism by which mycophenolate toxicities occur is unclear. Microarray analysis of liver and gut in rats treated with high-dose mycophenolate showed downregulation of the expression of the major ␣-hemoglobin, polymeric immunoglobulin receptor, catalase gene, and CCAAT/enhancer protein-␣, suggesting that these genes may be linked to adverse events (51) . Mycophenolate-treated rats had significantly lower erythrocytes and lymphocytes, and hemoglobin concentrations than untreated rats. In another study, significant drops in erythrocyte counts and hemoglobin were observed in rats after only 1 week of mycophenolate (52) . There was nearly a complete absence of hematopoietic progenitor cells in the bone marrow with reduced expression of major ␣-hemoglobin, catalase, and erythropoietin receptors in the bone marrow, suggesting suppression of erythropoiesis by mycophenolate. Interestingly in our analysis, a catalase SNP increased the risk of leukopenia in the single SNP analysis (Pϭ0.0093); however, it was not significant in the multiple-SNP model. This SNP requires further follow-up.
In summary, we identified multiple SNPs potentially associated with anemia and leukopenia, many of which have a strong biologic basis. Of interest, SNPs associated with anemia differed from those associated with leukopenia. However, these SNPs require independent confirmation in other centers. If these associations are confirmed, these finding may have clinical application and help to assess the toxicity risk pretransplantation. Patients with these risk SNPs may be more safely treated with azathioprine therapy. However, to our knowledge these novel SNPs have yet to be tested toward azathioprine toxicity.
MATERIALS AND METHODS
Study Design and Patients
This is a multicenter prospective study to identify SNPs associated with mycophenolate-related anemia and leukopenia. Subjects who received mycophenolate mofetil or mycophenolate sodium after kidney transplantation, for any period of time, between day of transplant and 6 months posttransplant were studied. Subjects were recruited from the Deterioration of Kidney Allograft Function (DeKAF) study, which is designed to characterize the causes of late allograft failure (53) (54) (55) . This study is registered at www.clinicaltrials.gov (NCT00270712). Transplant recipients were enrolled at time of transplant and were eligible if they were undergoing kidney or simultaneous kidney-pancreas transplantation. Written informed consent was obtained from all subjects and was approved by the institutional review boards of the participating institutions.
Mycophenolate-related anemia was defined as the use of mycophenolate at least 14 days before a hemoglobin less than 10 gm/dL (US centers) or hematocrit less than 30% (Canadian centers), that resulted in a clinical intervention. Clinical interventions were a mycophenolate dose reduction lasting more than or equal to 2 weeks, discontinuation for more than or equal to 2 weeks and initiation of erythropoietin therapy within 30 days of the onset of anemia. Anemia was considered not to be mycophenolate related if the patient had an active case of bleeding or antibody administration or a diagnosis of acute rejection within 2 weeks of anemia onset.
Mycophenolate-related leukopenia was defined as the use of mycophenolate at least 14 days before a WBC count less than 3000 cells/mm 3 that resulted in a clinical intervention. Clinical interventions were a mycophenolate dose reduction lasting more than or equal to 2 weeks, discontinuation for more than or equal to 2 weeks and/or initiation of granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor therapy within 30 days of the onset of the leukopenia. The leukopenia was considered not to be mycophenolate related if the subject had concurrent sepsis, an active CMV infection, or if the low WBC count was within 2 weeks of antibody administration or acute rejection. The time to anemia or leukopenia was calculated from first mycophenolate use to the date of the first respective low count.
Donor and recipient demographic information and drugs or class of drug prescribed over the 6-month study period were compiled. Drugs included were alemtuzumab, equine or rabbit antithymocyte globulin, basiliximab, daclizumab, azathioprine, corticosteroid, cyclosporine or tacrolimus, sirolimus, fluoxetine, flupenazine, captopril, enalapril, ticlopidine, fondaparinux, aspirin, heparin, clopidogrel, iron, erythropoietin, and antivirals. Acute rejection as diagnosed by the treating physician, allograft failure, and patient death during the first 6 months posttransplant were also recorded.
Genotyping
DNA was isolated from peripheral blood lymphocytes. Lymphocytes were isolated by centrifugation after RBC lysis and the DNA isolated. DNA was e IL12A increases hazard of anemia by 1.84 (84%) for every one allele relative to those recipients without the SNP.
SNP, single-nucleotide polymorphism; CI, confidence interval.
quantified by measuring the absorbance at 260 nm. Genotyping of SNPs was done using a customized Affymetrix GeneChip (56) . Additional SNPs were genotyped using the SNPlex (Applied Biosystems Inc., Foster City, CA) and Sequenom (Sequenom Inc., San Diego, CA) platforms. SNPs within genes associated with pathways affecting immunity, cell cycle, signaling, growth, proliferation, differentiation, movement, structure and death, inflammation, hematologic systems, and drug absorption, disposition, metabolism, and excretion were initially selected. Approximately 700 SNPs were related to drug absorption, disposition, metabolism, and excretion. Validated, functionally relevant polymorphisms including nonsynonymous SNPs with a MAF greater than 5%, and SNPs within conserved (in humans and mouse) transcriptional regulatory regions were chosen for genotyping. In the absence of functional SNPs, intragenic tagging SNPs were used. For quality control of genotyping data, negative controls (water) and duplicate samples (3% on Affymetrix, 7% on SNPlex, and 1% on Sequenom) were included in the analysis. Duplicate samples from 31 individuals genotyped on the Affymetrix platform exhibited more than 99% concordance. For all platforms, SNPs with concordance rates less than 90% and with call rates less than 60% were excluded. Twenty SNPs were run on multiple platforms and had a concordance rate of more than 97% and with call rates more than 82%. The Hardy-Weinberg equilibrium assumption was tested by chi-square analysis and SNPs that deviated from that assumption (PϽ1ϫ10 Ϫ6 ) were removed from the analysis. SNPs were excluded from further analysis if the MAF was less than 5% in the African American and non-African American groups; therefore, 2724 SNPs were used in the final analysis (see Appendix, Supplemental Digital Content 1, http://links.lww.com/TP/A321).
Association Testing of Clinical Factors and SNPs With Toxicity
Cox proportional hazards regression models were used to test the association between each SNP and time to anemia or time to leukopenia. Individuals were considered at risk of toxicity beginning on the day of transplant or first mycophenolate use, if mycophenolate was initiated after day of transplant. Censoring occurred at the earliest of death, graft failure, 14 days after permanent mycophenolate discontinuation, last date of follow-up, or 6 months posttransplant. Participants who temporarily stopped mycophenolate for reasons other than toxicity for more than 14 days were excluded from the risk set from 14 days after discontinuation until restarting mycophenolate.
Before testing for association of any SNPs, confounding clinical factors occurring in more than or equal to 5% of individuals were identified by backward selection with a retention P value less than 0.10 for time to anemia and leukopenia separately. Tested clinical factors were fixed covariates: gender, race, thymoglobulin induction, smoker, other tobacco use, age (linear and squared), weight (linear and squared), malignancy at baseline, primary cause of kidney failure, previous kidney transplant (yes/no), previous other transplant (yes/no), deceased or living donor, preemptive transplant (yes/ no), T or B cell cross match (yes/no), general panel reactive antibodies (PRA) (positive/negative), CMV status of recipient and donor (DϩRϪ, DϩRϩ, DϪRϪ, DϩRϩ), posttransplant dialysis (yes/no), blood type (A, B, AB, O) and SCr between days 6 to 8 posttransplant, and time-varying covariates (cyclosporine, tacrolimus, corticosteroids, ACE inhibitors, aspirin, clopidogrel, heparin and antiviral use at time of event) and were tested through regression analysis. Sirolimus was not evaluated because it was used in only 2.7% of recipients in the first 6 months. Age and weight were mean centered at 49.2 years and 81.4 kg, respectively. Unadjusted and adjusted Cox regression SNP models for time to anemia and leukopenia stratified by study center were conducted. Anemia SNP models were adjusted for age (linear), weight (linear and squared), posttransplant dialysis, and antiviral use. Leukopenia SNP models were adjusted for weight (linear), previous kidney transplant, deceased or living donor, CMV serostatus, and corticosteroid use.
Single-SNP Cox proportional hazards regression models were created for time to anemia and leukopenia by adding each SNP into a separate back- ground model. SNPs were coded for the additive genetic model. P values for SNP association were ordered in increasing order and denoted by P (1) , . . . , P (m) . They were considered significant if an FDR is less than 20%, that is, P (k) less than 0.2 k/m. We used an effective number of SNPs, mϭ2110, which was computed based on linkage disequilibrium between all SNPs (57) .
A Cox proportional hazards regression model with multiple SNPs was then developed for time to anemia. The top four SNPs from the single-SNP analyses ( Table 3 ) that were significant accounting for an FDR of 20% and the retained clinical factors were considered for entry into models. Because the two HUS1 SNPs (rs2037483 and rs1056663) are in high linkage disequilibrium (r 2 ϭ1.0), only the SNP with the least missing data, rs1056663, was used.
All statistical analyses were conducted using SAS/Genetics version 9.2 (The SAS Institute, Cary, NC, http://www.sas.com).
